ReviewFrontiers in medicine2022
Potential biomarkers of atopic dermatitis.
Review in Frontiers in medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 1 synthesis or guideline pooled it, 64 citations in OpenAlex.
- Biomarkers for therapeutic response and adverse outcomes in atopic dermatitis: A systematic review.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026Pooled it
- A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhibitor, in patients with mild to moderate atopic dermatitis: a proof-of-concept study withFrontiers in immunology · 2025Trial
- An AI-augmented review of childhood atopic dermatitis biomarkers across genetic, immune, microbial, and metabolic domains.Molecular medicine (Cambridge, Mass.) · 2026Review
- Activation of MyD88/IRAK1 axis and downstream proinflammatory signaling in healthy adult and neonatal African American skin.JID innovations : skin science from molecules to population health · 2026Article
- Single-Cell transcriptomic analysis reveals distinct cellular and molecular signatures of human oral mucosa and skin.Cellular and molecular life sciences : CMLS · 2026Article
- Translational insights into interleukin-driven macrophage polarization as diagnostic biomarkers for atopic dermatitis-a narrative review.Frontiers in molecular biosciences · 2026Review
- Atopic dermatitis: pathogenesis, immunology, microbiome, and salivary biomarkers.Frontiers in immunology · 2026Review
- Targeting the JAK/STAT pathway in atopic dermatitis.Frontiers in immunology · 2026Review
- Nitric oxide: a gas transmitter in healthy and diseased skin.Medical gas research · 2025Review
- Ethical challenges in biomarker research and precision medicine - a qualitative study in dermatology.BMC medical ethics · 2025Article
- Matrix Metalloproteinases in Inflammatory Dermatoses.International journal of molecular sciences · 2025Review
- Topical Steroid Withdrawal Is a Targetable Excess of Mitochondrial NAD.The Journal of investigative dermatology · 2025Article
- Predicting Favorable Conditions for the Determination of Initial Use of Janus Kinase Inhibitors in Patients with Moderate to Severe Atopic Dermatitis.Journal of clinical medicine · 2025Article
- Light-Activatable Hyaluronic Acid-Derivatives Releasing Nitric Oxide and Their Delivery in the Skin.Advanced healthcare materials · 2025Article
- Monocytes Expressing IL-36G Play a Crucial Role in Atopic Dermatitis.Journal of cellular and molecular medicine · 2025Article
- Biomarkers in Atopic Dermatitis: A Review of the Role of IL-13 and the Impact of Tralokinumab Treatment.American journal of clinical dermatology · 2025Review
- The novel house dust mite allergen Der p 39 exacerbates atopic dermatitis-like inflammation in mice by inducing skin barrier dysfunction.The World Allergy Organization journal · 2025Article
- Biomarkers in Atopic Dermatitis in Children: A Comprehensive Review.Life (Basel, Switzerland) · 2025Review
- Integrated Multi-Omics Analyses Reveal Innovative Diagnostic and Therapeutic Targets Associated with Atopic Dermatitis.Journal of inflammation research · 2025Article
- Enabling precision medicine with biomarkers of response to treatment in atopic dermatitis: where are we now? A narrative review.Frontiers in medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atopic dermatitis (AD) is a chronic, recurrent inflammatory skin disease with a wide range of heterogeneity. Accurate biomarkers or predictors are the keys to instructing personalized tailored precise treatment. The development of technology such as transcriptomics, genomics, and proteomics provides novel insights into the possibility to find potential biomarkers. Meanwhile, emerging minimally invasive methods such as tape stripping were used to reveal different profiles of patients' skin without biopsy. Several potential biomarkers or predictors have been found. In this review, we summarized the current development of potential biomarkers of AD. Nitric oxide synthase 2/inducible nitric oxide synthase (NOS2/iNOS), human beta-defensin-2 (hBD-2), and matrix metalloproteinases 8/9 (MMP8/9) may be the candidate biomarkers for AD diagnosis. Filaggrin (FLG) gene mutation increased the occurrence risk of AD. Fatty-acid-binding protein 5 (FABP5) may serve as an effective biomarker for the atopic march (AM). Squamous cell carcinoma antigen 2 (SCCA2), serum thymus and activation-regulated chemokine (TARC), cutaneous T-cell-attracting chemokine (CTACK), eosinophil-derived neurotoxin (EDN), macrophage-derived chemokine (MDC), lactate dehydrogenase (LDH), and interleukin (IL)-18 can be the candidate biomarkers for disease severity monitoring. IL-17, IL-23, IL-33, and indoleamine 2,3-dioxygenase (IDO1) can be used as predictive biomarkers for AD comorbidities. LDH, TARC, pulmonary and activation-regulated chemokine (PARC), periostin, IL-22, eotaxin-1/3, and IL-8 may be the candidate biomarkers for monitoring treatment effects. There are still unmet needs and a long way to go for more convenient, non-invasive, and effective predictors and biomarkers to better guide personalized precise treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.